Literature DB >> 6889461

Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.

R L Schilsky, A Barlock, R F Ozols.   

Abstract

Twenty-nine patients with nonseminomatous germ cell tumors of the testis have been followed for a median of 1.9 years (range 0.3-3.6) following completion of cisplatin-containing combination chemotherapy. Twenty-two of the 29 patients (76%) became hypomagnesemic during chemotherapy and, of these, 11 (50%) have remained persistently hypomagnesemic for as long as 3 years following discontinuation of cisplatin treatment. In the remaining patients, serum Mg levels returned to normal a median of 0.6 years (range, 0.2-2.1) after completion of chemotherapy. In eight of nine persistently hypomagnesemic patients studied, urinary Mg excretion was inappropriately elevated. Symptoms attributable to hypomagnesemia were rarely reported, although muscle cramps, twitching, or mild tremor were noted by the most severely hypomagnesemic patients. Continued followup of these patients is required to determine the effects of chronic hypomagnesemia in man.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6889461

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  23 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 4.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

5.  Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.

Authors:  C R Thomas; K J Stelzer; J G Douglas; W J Koh; L V Wood; R Panicker
Journal:  J Natl Med Assoc       Date:  1994-11       Impact factor: 1.798

6.  Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum?

Authors:  P E Ballmer; W H Reinhart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Does cisplatin-based chemotherapy effect on blood lipid levels of patients with germ cell testicular tumor in long-term follow-up?

Authors:  Gokhan Koc; Taner Rauf Divrik; Nuri Unlu; Volkan Bulut; Ferruh Zorlu
Journal:  Int Urol Nephrol       Date:  2011-04-20       Impact factor: 2.370

8.  Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats.

Authors:  Koji Yokoo; Risa Murakami; Takanobu Matsuzaki; Kanako Yoshitome; Akinobu Hamada; Hideyuki Saito
Journal:  Clin Exp Nephrol       Date:  2009-07-24       Impact factor: 2.801

Review 9.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

10.  Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy.

Authors:  Jennifer Faig; Michael Haughton; Richard C Taylor; Ralph B D'Agostino; Megan J Whelen; Kori A Porosnicu Rodriguez; Marcelo Bonomi; Mariana Murea; Mercedes Porosnicu
Journal:  Am J Clin Oncol       Date:  2018-05       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.